{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:06:36Z","timestamp":1790132796324,"version":"4.0.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,19]]},"abstract":"<jats:p>This study reports the efficacy of tralokinumab in five patients with bullous pemphigoid.<\/jats:p>","DOI":"10.1093\/bjd\/ljaf035","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T11:42:47Z","timestamp":1738150967000},"page":"1124-1126","source":"Crossref","is-referenced-by-count":12,"title":["Off-label use of tralokinumab in the treatment of bullous pemphigoid: a case series"],"prefix":"10.1093","volume":"192","author":[{"given":"Roberto","family":"Maglie","sequence":"first","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Didona","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Philipps-Universit\u00e4t Marburg , Marburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-5407","authenticated-orcid":false,"given":"Farzan","family":"Solimani","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5211-8228","authenticated-orcid":false,"given":"Carlo","family":"Pipit\u00f2","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8454-7617","authenticated-orcid":false,"given":"Maria Efenesia","family":"Baffa","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hertl","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Philipps-Universit\u00e4t Marburg , Marburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7787-4433","authenticated-orcid":false,"given":"Emiliano","family":"Antiga","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"2025052712590867500_ljaf035-B1","first-page":"1188","article-title":"Pemphigus and pemphigoids: clinical presentation, diagnosis and therapy","volume":"21","author":"Didona","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025052712590867500_ljaf035-B2","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2\u2005K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025052712590867500_ljaf035-B3","doi-asserted-by":"crossref","first-page":"1128154","DOI":"10.3389\/fmed.2023.1128154","article-title":"The cytokine milieu of bullous pemphigoid: current and novel therapeutic targets","volume":"10","author":"Maglie","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2025052712590867500_ljaf035-B4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025052712590867500_ljaf035-B5","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1111\/jdv.18673","article-title":"Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab","volume":"37","author":"Baffa","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025052712590867500_ljaf035-B6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaad.2019.07.060","article-title":"Pathophysiologic mechanisms of itch in bullous pemphigoid","volume":"83","author":"Hashimoto","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025052712590867500_ljaf035-B7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/ced\/llad331","article-title":"Rapid and sustained response to tralokinumab in a patient with severe bullous pemphigoid and end-stage kidney disease","volume":"49","author":"Maglie","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"2025052712590867500_ljaf035-B8","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1038\/s41467-024-50283-3","article-title":"Single-cell transcriptomics analysis of bullous pemphigoid unveils immune\u2013stromal crosstalk in type 2 inflammatory disease","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"2025052712590867500_ljaf035-B9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025052712590867500_ljaf035-B10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf035\/61668092\/ljaf035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/6\/1124\/61668092\/ljaf035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/6\/1124\/61668092\/ljaf035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:00:24Z","timestamp":1748365224000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/6\/1124\/7986099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,1,29]]},"published-print":{"date-parts":[[2025,5,19]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf035","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,1,29]]}}}